Larimar Therapeutics Inc (LRMR) Stock Analysis

Larimar Therapeutics Inc (LRMR) is a publicly traded company in the HEALTHCARE sector. It trades at $3.30, carries a market capitalization of $364.63M. This page summarizes the public market data, fundamentals, and frequently asked questions for LRMR, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $3.30
• Market Cap: $364.63M
• EPS: $-2.12
• 52-Week High: $6.42
• 52-Week Low: $2.22

Market Sentiment

Larimar Therapeutics Inc currently has a Bullish sentiment score of 0.45.

About Larimar Therapeutics Inc

Larimar Therapeutics, Inc. is a clinical-stage biotechnology company based in Bala Cynwyd, Pennsylvania, focused on developing innovative therapies for rare diseases characterized by significant unmet medical needs. Leveraging advanced technologies and deep scientific expertise, the company is committed to improving patient outcomes through its promising drug pipeline. With strategic partnerships and a clear vision for leadership in the rare disease sector, Larimar is well-positioned to deliv...

GNG Research Analysis

GNG Research scores Larimar Therapeutics Inc (LRMR) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for LRMR.

Frequently Asked Questions

Does LRMR pay dividends?

Larimar Therapeutics Inc (LRMR) does not currently pay a regular dividend.

What is LRMR's market cap?

Larimar Therapeutics Inc (LRMR) has a market capitalization of $364.63M with a current stock price of $3.30.